HIGHLIGHTS
- who: Sara Manti and collaborators from the University of Messina, Via Consolare Valeria, , Messina, Italy have published the Article: Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease, in the Journal: (JOURNAL)
- what: The extension phase of this trial showed the long-term safety and efficacy of ligelizumab. Although it is not the purpose of this review, it is necessary to mention that, among biologic drugs, small_molecule inhibitors such as remibrutinib (LOU064), a Bruton's tyrosine kinase (BTK) inhibitor with a potential role in the treatment of CSU, represent an alternative . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.